Key facts
- This page summarizes Stephane Bancel's Form 4 filing for Moderna, Inc. (MRNA).
- 10 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 07 Aug 2026, 16:11.
Stephane Bancel - 05 Aug 2026 Form 4 Insider Report for Moderna, Inc. (MRNA)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- MRNA
- Reported as of
- 05 Aug 2026
- Net transaction value
- -$28,715,011
- SEC form
- 4
- Accepted by SEC
- 07 Aug 2026, 16:11:02 UTC
- Prior SEC filing
- 03 Mar 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ James Dillon, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Stephane Bancel filed Form 4 for Moderna, Inc. (MRNA) on 07 Aug 2026.
Change
- Previous filing in this sequence was filed on 03 Mar 2026.
- Current net transaction value: -$28,715,011.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001443340
Primary reporting owner
Bancel Stephane
- Relationship
- Chief Executive Officer, Director
- Address
- C/O MODERNA, INC., 325 BINNEY STREET, CAMBRIDGE
- Signature
- /s/ James Dillon, as Attorney-in-Fact
- Signature date
- 07 Aug 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MRNA
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +499,246
- Change %
- +8.1%
- Price
- $19.15*
- Shares after
- 6,687,037
- Date
- 05 Aug 2026
- Ownership
- Direct
- Footnotes
- F1
MRNA
transaction
Common Stock
Sale
- Transaction value
- $8,289,457
- Shares
- -147,473
- Change %
- -2.2%
- Price
- $56.21
- Shares after
- 6,539,564
- Date
- 05 Aug 2026
- Ownership
- Direct
- Footnotes
- F1, F2
MRNA
transaction
Common Stock
Sale
- Transaction value
- $7,110,772
- Shares
- -124,838
- Change %
- -1.9%
- Price
- $56.96
- Shares after
- 6,414,726
- Date
- 05 Aug 2026
- Ownership
- Direct
- Footnotes
- F1, F3
MRNA
transaction
Common Stock
Sale
- Transaction value
- $2,318,465
- Shares
- -39,891
- Change %
- -0.62%
- Price
- $58.12
- Shares after
- 6,374,835
- Date
- 05 Aug 2026
- Ownership
- Direct
- Footnotes
- F1, F4
MRNA
transaction
Common Stock
Sale
- Transaction value
- $10,996,317
- Shares
- -187,044
- Change %
- -2.9%
- Price
- $58.79
- Shares after
- 6,187,791
- Date
- 05 Aug 2026
- Ownership
- Direct
- Footnotes
- F1, F5
MRNA
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +252,469
- Change %
- +4.1%
- Price
- $19.15*
- Shares after
- 6,440,260
- Date
- 06 Aug 2026
- Ownership
- Direct
- Footnotes
- F1
MRNA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 9,210,686
- Date
- 05 Aug 2026
- Ownership
- See Footnote
- Footnotes
- F6
MRNA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 6,564,880
- Date
- 05 Aug 2026
- Ownership
- See Footnote
- Footnotes
- F7
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MRNA
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -370,853
- Change %
- -66%
- Price
- $0.000000*
- Shares after
- 187,541
- Date
- 05 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 370,853
- Exercise price
- $19.15
- Footnotes
- F1, F8
MRNA
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -128,393
- Change %
- -66%
- Price
- $0.000000*
- Shares after
- 64,928
- Date
- 05 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 128,393
- Exercise price
- $19.15
- Footnotes
- F1, F8
MRNA
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -187,541
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 06 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 187,541
- Exercise price
- $19.15
- Footnotes
- F1, F8
MRNA
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -64,928
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 06 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 64,928
- Exercise price
- $19.15
- Footnotes
- F1, F8
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 8 footnotes
Footnote F1
The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 4, 2026. The Reporting Person exercised in full two stock option awards that were scheduled to expire on August 10, 2026. The options would have been forfeited if not exercised prior to their expiration date. In connection with the cashless exercise and hold transaction, the Reporting Person sold 499,246 shares acquired upon exercise solely to cover the exercise price, applicable withholding taxes, and related transaction costs, and retained all remaining shares of common stock acquired upon exercise.
Footnote F2
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $55.58 to $56.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Footnote F3
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $56.59 to $57.59. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Footnote F4
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $57.60 to $58.59. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Footnote F5
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $58.61 to $59.34. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Footnote F6
These shares are owned directly by Boston Biotech Ventures. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
Footnote F7
These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
Footnote F8
This option is fully vested and exercisable.